This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Opportunities Are Still Out There

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Leadership is a wonderful thing, Jim Cramer said on Mad Money Tuesday. Cramer said investors may have already missed the bottom but there are still plenty of opportunities left to come.

There have been many sectors that have not been participating in the market's rally, Cramer continued, including the high-growth tech names, retail, the airlines and most of all, biotech. All of these sectors have been left for dead, he noted -- until today.

Netflix (NFLX) spurred the high-growth tech names today as that high-multiple stock with no earnings proved that its model works internationally, sending shares up 7% on the day, and taking others like Yelp (YELP) and Zillow (Z) along for the ride.

A takeover bid for Allergan (AGN) was enough to spark the biotech and health care sectors into action, Cramer noted. Many of these high-fliers now seem undervalued.

The retail sector also turned positive today on an upgrade of Home Depot (HD), which sent those shares up a quick 2%. The airlines also ended in the green, thanks to continued weakness in crude oil.

Cramer said the markets are still full of skeptics and critics who will panic at the drop of a hat. But when the markets take their next pause, that will certainly be the time to buy into these new market leaders.

Allergan vs. Valeant

"I'm a big fan of mergers and acquisitions," Cramer told viewers -- but not the recently announced planned hostile takeover of Allergan by Valeant Pharmaceuticals (VRX) for $45 billion.

Cramer said he's long been a fan of Allergan and CEO David Pyott. The company has a brilliant strategy and is becoming a powerhouse in everything from eye care and obesity to migraines and incontinence treatments.

When the analysts feared generic competition to Allergan's eye care treatments last year, Pyott told Mad Money viewers not to worry. Turns out the analysts were dead wrong, which is why Allergan shares more than doubled since then and were up 28% so far this year, before today's announcement.

So why not support the Valeant takeover? Cramer said Valeant needs to make acquisitions in order to keep growing, and if this deal goes through Allergan will likely end up like many of Valeant's other takeovers -- a shell of its former self.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AGN $240.22 1.21%
HAL $47.36 -1.00%
GME $39.87 -1.10%
VRTX $133.55 6.40%
AAPL $126.90 -0.55%

Markets

DOW 18,000.99 -33.94 -0.19%
S&P 500 2,099.65 -0.75 -0.04%
NASDAQ 5,012.9980 +18.3960 0.37%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs